In today’s world, the global health landscape is often overshadowed by headlines about gun violence, accidents, or the ongoing COVID-19 pandemic. However, the real silent killers, responsible for nearly 50% of deaths in the U.S., are cardiovascular disease and cancer. Surprisingly, these seemingly distinct diseases share underlying similarities in their origins and development, paving the way for potentially groundbreaking treatments.
As a seasoned biomedical engineer with over two decades of experience, I have dedicated my career to enhancing drug delivery within the human body. Recent discoveries have shown that engineered nanoparticles, designed to target specific immune cells, could hold the key to treating both cancer and cardiovascular disease effectively.
Cardiovascular disease encompasses a range of conditions, with atherosclerosis being the deadliest form. It results from inflammation and the accumulation of fats and cholesterol in blood vessel walls, leading to plaque formation. The rupture of these plaques is a major cause of heart attacks. Interestingly, cancer, on the other hand, is primarily driven by genetic mutations that trigger uncontrollable cell division, often causing destruction that is difficult to halt without harming healthy organs.
Despite their differing origins, cardiovascular disease and cancer share numerous risk factors. Lifestyle choices such as obesity, smoking, chronic stress, and poor diet are common culprits for both diseases. These shared risk factors can be traced back to chronic inflammation, a fundamental driver for both conditions.
Chronic inflammation damages blood vessel cells, worsening atherosclerosis, and increasing the risk of plaque rupture. In the case of cancer, inflammation fosters genetic mutations, supports cancer cell survival, and promotes the growth of blood vessels that feed tumors while suppressing the body’s immune response.
Excitingly, therapies initially designed for cancer treatment have shown promise in combating atherosclerosis. For instance, drugs targeting immune cells known as macrophages in tumors can also help clear dead and dying cells in atherosclerosis, shrinking plaques. Additionally, antiglycolytic therapies that prevent glucose breakdown, traditionally used for cancer, can normalize diseased blood vessels and reduce inflammation in atherosclerosis.
Current treatments like statins and fibrates, while effective to some extent, have not adequately addressed cardiovascular disease’s mortality risk. Researchers have turned to sodium-glucose cotransporter-2 inhibitors, originally used for diabetes, which have shown significant protection against cardiovascular disease while also exhibiting anti-cancer properties.
Clinical trials have revealed the interconnectedness of inflammation, metabolism, and cardiovascular disease, opening up new avenues for treatment. Immunotherapies that unleash the immune system’s full potential have not only shown promise in cancer but have also reduced atherosclerotic plaques and vascular inflammation in animal and human studies.
In a groundbreaking recent discovery, nanotubes, ultra-small carbon particles, have demonstrated the ability to enter specific immune cells, travel through the bloodstream, and target tumors effectively. Researchers are exploring whether these nanotube-loaded immune cells can serve as delivery vehicles for plaque-reducing therapies, potentially revolutionizing cardiovascular disease treatment. Furthermore, nanoparticles can enter tumors through leaky blood vessels, a phenomenon known as the enhanced permeation and retention effect, offering a promising avenue for improving drug delivery in cardiovascular disease.
Given the shared molecular pathways between cancer and cardiovascular disease, nanoparticle-based cancer drugs may hold great promise as candidates for cardiovascular disease treatment and vice versa. As our understanding of these diseases’ molecular parallels continues to grow, patients stand to benefit from more effective therapies capable of addressing both conditions simultaneously.
In conclusion, the convergence of biomedical engineering, nanoparticle technology, and cutting-edge research is opening doors to innovative treatments that could transform the way we combat cardiovascular disease and cancer, ultimately improving the lives of countless individuals.
Link to original article posted on JapanToday by Bryan Smith
